Skip to main content

Table 3 Post-hoc analysis of mGFR change by excluding patients who had an outlier mGFR result (ANCOVA)

From: Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial

  mGFR (mL/min/1.73 m 2 )
  Tofacitinib → placebo group Placebo → placebo group
Change at end of period 1 from baseline
Number 76 37
Adjusted geometric mean fold-change (90% CI) 0.91 (0.88, 0.93) 1.01 (0.97, 1.04)
Ratio of adjusted geometric mean fold-change (90% CI) 0.90 (0.86, 0.94)
Change at end of period 2 from baseline
Number 72 36
Adjusted geometric mean fold-change (90% CI) 0.96 (0.93, 0.99) 0.98 (0.94, 1.01)
Ratio of adjusted geometric mean fold-change (90% CI) 0.98 (0.94, 1.03)
Change at end of period 2 from end of period 1
Number 72 36
Adjusted geometric mean fold-change (90% CI) 1.06 (1.03, 1.09) 0.99 (0.95, 1.03)
Ratio of adjusted geometric mean fold-change (90% CI) 1.07 (1.02, 1.12)
  1. Post-hoc analysis excluded those patients with a difference between mGFR and eGFR falling outside the 95% limits of agreement between the two methods of measurement. ANCOVA, analysis of covariance; eGFR, estimated glomerular filtration rate; mGFR, measured glomerular filtration rate.